Compare Cytokinetics Inc (CYTK) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ING Groep NV — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while ING Groep NV trades at $33.15 (market cap $96.81B). The key difference: ING Groep NV is far larger — about 11.4× Cytokinetics Inc's market cap, and ING Groep NV pays a 3.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and ING Groep NV for 93 Days on average.
| CYTK | ING | |
|---|---|---|
Market Cap | $8.50B | $96.81B |
Volume | 2,395,556 | 2,635,505 |
Sector | Health | Financials |
52-Week High | $87.26 | $37.27 |
52-Week Low | $54.76 | $23.66 |
Typical Hold Time | 19 Days | 93 Days |
Enterprise Value | $8.60B | $236.31B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
ING stock trades at $33.43, down 4.21% with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q2 2026 EPS of $0.79 versus $0.75 expected. Revenue growth remains steady at $22.9B in 2025 with a robust 28.34% net margin. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations.
The stock presents a value opportunity with a reasonable P/E of 13.09 and strong profitability metrics, though negative cash flow trends and regulatory challenges in Australia warrant monitoring. Management's raised ROE target above 16% for 2027 signals confidence in continued operational improvement and strategic execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
